^
    2d
    177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of California, San Francisco | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    5d
    PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan (clinicaltrials.gov)
    P=N/A, N=753, Not yet recruiting, Novartis Pharmaceuticals
    New trial
    |
    FOLH1 positive
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    8d
    A Real-world Study of Characteristics, Treatment Patterns, and Clinical Outcomes Among Lutetium-177 Vipivotide Tetraxetan Treated Patients (clinicaltrials.gov)
    P=N/A, N=1247, Completed, Novartis Pharmaceuticals
    New trial • Real-world evidence
    |
    carboplatin • docetaxel • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Provenge (sipuleucel-T)
    9d
    Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan (clinicaltrials.gov)
    P2, N=87, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    12d
    Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial (clinicaltrials.gov)
    P2, N=40, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    14d
    NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2027 --> Aug 2026 | Trial primary completion date: Jun 2027 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • SSTR2 (Somatostatin Receptor 2) • SYP (Synaptophysin) • CHGA (Chromogranin A)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Lutathera (lutetium Lu 177 dotatate) • AAA603
    17d
    CAMO959A12103: A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSMA-positive prostate cancer that has spread to other parts of the body.athway inhibitor (ARPI) in adults with PSMA-positive prostate cancer that has spread to other parts of the body. (2025-521859-23-00)
    P1/2, N=61, Not yet recruiting, Novartis Pharma AG
    New P1/2 trial
    |
    Xtandi (enzalutamide) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Firmagon (degarelix) • Orgovyx (relugolix)
    20d
    NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial (clinicaltrials.gov)
    P1/2, N=6, Active, not recruiting, M.D. Anderson Cancer Center | N=36 --> 6 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    Firmagon (degarelix)
    20d
    Real-world Use of Lutetium (177Lu) Vipivotide Tetraxetan in China(PSMAreal CN) (clinicaltrials.gov)
    P=N/A, N=170, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    21d
    A Study of Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617 (clinicaltrials.gov)
    P=N/A, N=6448, Completed, Novartis Pharmaceuticals
    New trial
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    21d
    STAMPEDE2: A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (clinicaltrials.gov)
    P3, N=296, Recruiting, University College, London | N=76 --> 296
    Enrollment change
    |
    docetaxel • Xtandi (enzalutamide) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    22d
    PSMACare: A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC (clinicaltrials.gov)
    P2, N=49, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2030 --> Dec 2026 | Trial primary completion date: Apr 2028 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    FOLH1 positive
    |
    Xtandi (enzalutamide) • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)